Life sciences company Avantor (NYSE:AVTR) announced better-than-expected revenue in Q1 CY2026, but sales were flat year on year at $1.58 billion. Its non-GAA...
Life sciences company Avantor (NYSE:AVTR) reported Q1 CY2026 results beating Wall Street’s revenue expectations, but sales were flat year on year at $1.58 bi...
Life sciences company Avantor (NYSE:AVTR) will be reporting earnings this Wednesday before market hours. Here’s what to expect. Avantor beat analysts’ revenu...
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the research tools & consumables industry, including Avantor (NYS...
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ...
Hitting a new 52-week low can be a pivotal moment for any stock. These floors often mark either the beginning of a turnaround story or confirmation that a co...
What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in...
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...
Avantor has gotten torched over the last six months - since September 2025, its stock price has dropped 38% to a new 52-week low of $7.88 per share. This may...
What Happened? A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected contraction in employment, with the hea...
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have...
Avantor’s fourth quarter was marked by a negative market reaction, as investors responded to a 1.4% year-over-year revenue decline and operating margin compression. Management attributed these results to ongoing operational changes under its newly launched Revival program and highlighted external pressures, particularly in the laboratory solutions and bioscience production segments. CEO Emmanuel Ligner described 2025 as a “challenging year” and stressed that pricing actions in the lab business, combined with unfavorable mix, weighed on margins. He also noted, “2026 will be a year of transition and investment as we reinforce the foundation of this great company.”
Life sciences company Avantor (NYSE:AVTR) announced better-than-expected revenue in Q4 CY2025, but sales fell by 1.4% year on year to $1.66 billion. Its non-GAAP profit of $0.22 per share was in line with analysts’ consensus estimates.
